(Q34335616)

English

Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

Europe PubMed Central

Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Grossfeld GD

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Small EJ

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Lubeck DP

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Latini D

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Broering JM

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Carroll PR

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

1 August 2001

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

2 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

56-64

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent androgen suppression in the management of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of intermittent androgen deprivation in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent endocrine therapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Current status of intermittent androgen suppression in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent endocrine therapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The RAND 36-Item Health Survey 1.0.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical profile of a new non-steroidal antiandrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with finasteride following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined finasteride and flutamide therapy in men with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901243-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(01)01243-2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34335616&oldid=2038940398"